This was the stock's third consecutive day of gains.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Clearly, options traders are pricing in a big move for Vertex Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Vertex Pharmaceuticals is a Zacks Rank #3 ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...